Prils Market Share

  • Report ID: 4109
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Prils Market Share

North American Market Forecast

The prils market in North America is projected to be the largest with a share of about 41% by the end of 2037. The growth of the market can be attributed majorly to the increasing cases of obesity. For instance, the chance of developing hypertension and other cardiovascular disorders increases with obesity, which could result in a rise in the demand for hypertension drugs.

Further, the growing healthcare infrastructure in the region, along with the high prevalence of neurological disorders, is also anticipated to contribute to the market growth in the region. According to estimates, between 2017 and 2020, more than 40% of US people were obese, making it one of the most prevalent health issues in the country.

European Market Statistics

Europe industry is predicted to account for largest revenue share of 31% by 2037. The growth of the market can be attributed majorly to the increasing initiatives to assist the expansion of generic medications through pricing and reimbursement. Generic prils may be used more frequently as a result, which could raise demand for these drugs.

In addition, the region's favorable government policies and surging expenditure on research and development activities are also anticipated to boost market growth during the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4109
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of prils is evaluated at USD 2.51 billion.

The prils market size was valued at USD 2.27 billion in 2024 and is expected to reach USD 5.08 billion by 2037, expanding at around 6.4% CAGR during the forecast period i.e., between 2025-2037. Rising geriatric population and the growing incidences of cardiovascular diseases will boost the market growth.

Europe industry is predicted to account for largest revenue share of 31% by 2037, driven by increasing initiatives to assist the expansion of generic medications through pricing and reimbursement in the region.

The major players in the market are Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample